Our Global Business Unit (GBU) at Jawaharpur, Derabassi stands as a symbol of Ind-Swift’s commitment to world-class pharmaceutical manufacturing. As a 100% export-oriented unit, this facility is designed to meet the stringent regulatory requirements of global markets, including MHRA, Health-Canada, and other major health authorities.

Strategically built with advanced automation, streamlined production lines, and robust quality systems, the plant ensures efficient, high-volume manufacturing across key therapeutic segments. From formulation development to commercial-scale production, every process is backed by cutting-edge technology and a skilled workforce. This state-of-the-art infrastructure reinforces our promise to deliver quality, consistency, and compliance—enabling us to serve partners across the globe with confidence.

Own Marketing Setup

Strong presence in domestic and international markets through our in-house marketing and sales teams across various therapeutic segments.

Our operations are driven by automation, lean practices, and a continuous improvement mindset, allowing us to deliver consistent quality with speed and efficiency.

At Ind-Swift Group, our diversified business model is designed to create long-term value through multiple engagement avenues across the pharmaceutical value chain. We collaborate with partners worldwide through flexible and growth-driven approaches.

Dossier Out-Licensing

Offering high-quality, CTD-compliant dossiers for out-licensing in regulated and semi-regulated markets, enabling partners to register and commercialize products efficiently.

Contract Research &
Contract Development

End-to-end support from formulation development to scale-up, regulatory documentation, and clinical support — all under strict quality and confidentiality norms.